Elamin H Elbasha

List of Publications by Year
in descending order

46 papers	2,568 citations	257450 24 h-index	243625 44 g-index
47 all docs	47 docs citations	47 times ranked	2984 citing authors

#	Article	IF	Citations
1	Model for Assessing Human Papillomavirus Vaccination Strategies. Emerging Infectious Diseases, 2007, 13, 28-41.	4.3	419
2	Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology, 2013, 57, 2164-2170.	7.3	397
3	Impact of vaccinating boys and men against HPV in the United States. Vaccine, 2010, 28, 6858-6867.	3.8	192
4	Mathematical Models for Predicting the Epidemiologic and Economic Impact of Vaccination against Human Papillomavirus Infection and Disease. Epidemiologic Reviews, 2006, 28, 88-100.	3.5	146
5	Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infectious Diseases, 2009, 9, 119.	2.9	120
6	A primer on using mathematics to understand COVID-19 dynamics: Modeling, analysis and simulations. Infectious Disease Modelling, 2021, 6, 148-168.	1.9	98
7	Theoretical Assessment of Public Health Impact of Imperfect Prophylactic HIV-1 Vaccines with Therapeutic Benefits. Bulletin of Mathematical Biology, 2006, 68, 577-614.	1.9	93
8	Vaccination against multiple HPV types. Mathematical Biosciences, 2005, 197, 88-117.	1.9	87
9	Incidence and Duration of Cervical Human Papillomavirus 6, 11, 16, and 18 Infections in Young Women: An Evaluation from Multiple Analytic Perspectives. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 709-715.	2.5	83
10	Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: A transmission dynamic model-based evaluation. Vaccine, 2007, 26, 128-139.	3.8	81
11	On Endogenous Growth: The Implications of Environmental Externalities. Journal of Environmental Economics and Management, 1996, 31, 240-268.	4.7	70
12	Cost-Effectiveness of Boceprevir in Patients Previously Treated for Chronic Hepatitis C Genotype 1 Infection in the United States. Value in Health, 2013, 16, 973-986.	0.3	63
13	Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women. Infectious Agents and Cancer, 2007, 2, 15.	2.6	57
14	A Multi-Type HPV Transmission Model. Bulletin of Mathematical Biology, 2008, 70, 2126-2176.	1.9	54
15	The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States. Clinical Infectious Diseases, 2016, 62, 298-304.	5.8	46
16	Cost-effectiveness analysis and health care resource allocation: decision rules under variable returns to scale. Health Economics (United Kingdom), 2004, 13, 21-35.	1.7	43
17	Changing Cycle Lengths in State-Transition Models. Medical Decision Making, 2016, 36, 952-964.	2.4	38
18	Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models. BMC Medicine, 2011, 9, 54.	5.5	37

#	ARTICLE	IF	CITATIONS
19	Global Stability of Equilibria in a Two-Sex HPV Vaccination Model. Bulletin of Mathematical Biology, 2008, 70, 894-909.	1.9	34
20	Cost-Effectiveness Analysis of Boceprevir for the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection in Portugal. Applied Health Economics and Health Policy, 2013, 11, 65-78.	2.1	34
21	Public Health Impact and Cost-Effectiveness of Hepatitis A Vaccination in the United States: A Disease Transmission Dynamic Modeling Approach. Value in Health, 2015, 18, 358-367.	0.3	32
22	Model for hepatitis C virus transmissions. Mathematical Biosciences and Engineering, 2013, 10, 1045-1065.	1.9	28
23	Age-Based Programs for Vaccination against HPV. Value in Health, 2009, 12, 697-707.	0.3	27
24	Assessment of the cost–effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model. Expert Review of Pharmacoeconomics and Outcomes Research, 2008, 8, 491-500.	1.4	26
25	Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States. Human Vaccines and Immunotherapeutics, 2021, 17, 1943-1951.	3.3	24
26	The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary. Journal of Medical Economics, 2010, 13, 110-118.	2.1	23
27	Theoretical Foundations and Practical Applications of Within-Cycle Correction Methods. Medical Decision Making, 2016, 36, 115-131.	2.4	23
28	Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach. Health Economics (United Kingdom), 2005, 14, 457-470.	1.7	20
29	Vaccination and the evolutionary ecology of human papillomavirus. Vaccine, 2008, 26, C25-C30.	3.8	20
30	Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision Makers. Pharmacoeconomics, 2016, 34, 13-22.	3.3	18
31	Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study. BMC Infectious Diseases, 2021, 21, 11.	2.9	17
32	Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France. Vaccine, 2021, 39, 438-446.	3.8	16
33	Structural differences among cost–effectiveness models of human papillomavirus vaccines. Expert Review of Vaccines, 2008, 7, 895-913.	4.4	14
34	Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection. Value in Health, 2017, 20, 1110-1120.	0.3	14
35	Cost-Effectiveness of Boceprevir Co-Administration versus Pegylated Interferon-β2b and Ribavirin Only for Patients with Hepatitis C Genotype 1 in Singapore. Antiviral Therapy, 2015, 20, 209-216.	1.0	13
36	Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview. Pharmacoeconomics, 2017, 35, 673-683.	3.3	13

#	Article	IF	Citations
37	Public health impact and cost effectiveness of routine childhood vaccination for hepatitis a in Jordan: a dynamic model approach. BMC Infectious Diseases, 2018, 18, 119.	2.9	9
38	Qualitative analysis of an age- and sex-structured vaccination model for human papillomavirus. Discrete and Continuous Dynamical Systems - Series B, 2013, 18, 2151-2174.	0.9	7
39	The Cost-Effectiveness Analysis of a Quadrivalent Human Papillomavirus Vaccine (6/11/16/18) for Females in Japan. Value in Health Regional Issues, 2013, 2, 92-97.	1.2	6
40	Cost‑Effectiveness Risk‑Aversion Curves: Comparison of Risk-Adjusted Performance Measures and Expected-Utility Approaches. Pharmacoeconomics, 2022, 40, 497-507.	3.3	6
41	Characterizing Heterogeneity Bias in Cohort-Based Models. Pharmacoeconomics, 2015, 33, 857-865.	3.3	4
42	Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination regimen in a high-income country setting: An analysis in the United Kingdom. Vaccine, 2022, 40, 2173-2183.	3.8	4
43	Cost-effectiveness of routine catch-up hepatitis a vaccination in the United States: Dynamic transmission modeling study. Vaccine, 2021, 39, 6315-6321.	3.8	3
44	Projected impact of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 and chronic kidney disease in Vietnam. Journal of Infection and Public Health, 2019, 12, 502-508.	4.1	1
45	Authors' Reply to Comment on "Risk-Adjusted Performance Measures". Pharmacoeconomics, 0, , .	3.3	1
46	Mathematical assessment of the impact of cohort vaccination on pneumococcal carriage and serotype replacement. Journal of Biological Dynamics, 2021, 15, S214-S247.	1.7	0